Patents by Inventor Myles Wolf

Myles Wolf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160039936
    Abstract: Methods of inhibiting fibroblast growth factor mediated activation of fibroblast growth factor receptors for the treatment of chronic kidney disease, diabetes, obesity, and cardiac diseases are enclosed. Pharmaceutical compositions for the treatment of such diseases using the methods are also disclosed as are methods of determining whether a subject would benefit from the methods of treatment and pharmaceutical compositions.
    Type: Application
    Filed: August 4, 2015
    Publication date: February 11, 2016
    Inventors: Christian Faul, Myles Wolf
  • Publication number: 20140294820
    Abstract: Methods of inhibiting fibroblast growth factor mediated activation of fibroblast growth factor receptors for the treatment of chronic kidney disease, diabetes, and cardiac diseases are enclosed. Pharmaceutical compositions for the treatment of such diseases using the methods are also disclosed as are methods of determining whether a subject would benefit from the methods of treatment and pharmaceutical compositions.
    Type: Application
    Filed: June 14, 2012
    Publication date: October 2, 2014
    Applicant: UNIVERSITY OF MIAMI
    Inventors: Christian Faul, Myles Wolf
  • Publication number: 20110183434
    Abstract: The present invention describes the ability to identify chronic kidney disease (CKD) mortality risk in asymptomatic patients. For example, a patient having a normal glomerular filtration rate would be considered likely to have an increased mortality risk for chronic kidney disease upon the detection of an FGF-23 amino acid sequence that is above a normal level, but below CKD Stage 1 levels. Consequently, therapeutic strategies may be implements to prevent morbidity and mortality following chronic kidney disease progression. Such therapeutic strategies can involve phosphate reduction strategies (i.e., for example, reduced dietary intake of phosphorus and/or administration of phosphate binding compound). Further, kits are described providing instruction to determine a specific mortality risk based upon measured FGF-23 levels and estimated glomerular filtration rates.
    Type: Application
    Filed: January 15, 2009
    Publication date: July 28, 2011
    Inventor: Myles Wolf
  • Publication number: 20050148023
    Abstract: The invention relates to methods and compositions for identifying pregnant subjects having, or predisposed to having, gestational diabetes, preeclampsia, and gestational hypertension. The methods are applicable to urine and/or blood samples and can be conducted prior to the third trimester of pregnancy, and as early as the first trimester.
    Type: Application
    Filed: August 16, 2004
    Publication date: July 7, 2005
    Inventors: Ravi Thadhani, Myles Wolf, Tanya Knickerbocker, Gavin MacBeath